Stay updated with breaking news from Allan pantuck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a late-stage preclinical biotech company using artificial intelligence to develop small molecule...
/PRNewswire/ -- Athos Therapeutics, Inc. (the "Company"), a late-stage preclinical biotech company using artificial intelligence to develop small molecule...
Abraham Verghese MD, Noted Stanford Physician and Recipient of the National Humanities Medal at the White House from former President Obama, Appointed to the Board of Directors of Athos Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Article content MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in the Phase III ZIRCON 1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx ( 89Zr-girentuximab) in the United States. The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth. The ZIRCON trial, which includes twelve participating clinical study sites across the U.S. and Canada, initiated patient recruitment in U.S. on Friday, with the first patients being dosed with TLX250-CDx at University of California, Los Angeles (UCLA), and Seattle Cancer Care Alliance, University of Washington, Seattle (SCCA). The remaining seven U.S. sites